Merck & Co (MRK) Stock

On Monday, Merck & Co Inc MRK announced the main findings from the Phase 3 ZENITH study, which looked at Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who are in functional class (FC) III or IV and at high risk of death.

Many investors today get caught up in the excitement of trends. However, the true worth is found in stocks that offer reliable and strong dividend yields without all the distractions. Rather than following the latest fads, concentrating on undervalued high-yield dividend stocks is a wise approach to growing wealth over time.

We think that investors looking to hold their investments for a long time should keep their MRK stock, but those focused on short-term gains might want to sell it.

Merck & Co., Inc. (NYSE:MRK) will be participating in the Jefferies London Healthcare Conference on November 21, 2024, at 6:30 AM ET. The corporate representatives include Joe Romanelli, President of Human Health International, and Marjorie Green, Senior Vice President and Head of Oncology at Merck Research Laboratories. Akash Tewari from Jefferies is also on the call, welcoming everyone to the final day of the conference.

Angelica Peebles from CNBC shares updates about Merck.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck has declared its dividend for the first quarter of 2025.

The CHMP has given a favorable recommendation for the approval of MRK's Keytruda as a first-line treatment for malignant pleural mesothelioma.

In my newest article, I share forecasts for upcoming dividend increases from companies known for their long-term growth in dividends. I anticipate that 10 companies will reveal their annual increases in the latter part of November, with Merck expected to have small increases and Raymond James Financial likely to announce over a 10% increase. Additionally, Hormel Foods is set to declare its 59th consecutive year of dividend growth, showcasing its dedication to raising dividends.

MRK has obtained a bispecific antibody that works in the same way as SMMT's main drug, which did better than its popular drug, Keytruda, in a lung cancer trial.